{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:26:46Z","timestamp":1789097206547,"version":"build-2803163510"},"reference-count":44,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"am","delay-in-days":383,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016359"],"award-info":[{"award-number":["P30CA016359"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50CA196530"],"award-info":[{"award-number":["P50CA196530"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1CA240418"],"award-info":[{"award-number":["RO1CA240418"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA235747"],"award-info":[{"award-number":["U01CA235747"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R41AI134531"],"award-info":[{"award-number":["R41AI134531"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Chemical Biology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.chembiol.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T10:31:53Z","timestamp":1749465113000},"page":"839-853.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6019-0534","authenticated-orcid":false,"given":"Marta","family":"Baro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hojin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongliang","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chatchai","family":"Phoomak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Politi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline J.","family":"Zeiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Van Zandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Contessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chembiol.2025.05.005_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2025.05.005_bib2","doi-asserted-by":"crossref","first-page":"11672","DOI":"10.1021\/acs.jmedchem.3c01160","article-title":"Evolution of Slow-Binding Inhibitors Targeting Histone Deacetylase Isoforms","volume":"66","author":"Mukherjee","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.chembiol.2025.05.005_bib3","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1016\/j.molcel.2023.11.006","article-title":"ER chaperones use a protein folding and quality control glyco-code","volume":"83","author":"Guay","year":"2023","journal-title":"Mol. Cell"},{"key":"10.1016\/j.chembiol.2025.05.005_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105417","article-title":"Glycosylation network mapping and site-specific glycan maturation in vivo","volume":"25","author":"Losfeld","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.chembiol.2025.05.005_bib5","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2103592118","article-title":"UDP-glucose pyrophosphorylase 2, a regulator of glycogen synthesis and glycosylation, is critical for pancreatic cancer growth","volume":"118","author":"Wolfe","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.chembiol.2025.05.005_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105217","article-title":"Sialylation of EGFR by ST6GAL1 induces receptor activation and modulates trafficking dynamics","volume":"299","author":"Ankenbauer","year":"2023","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2025.05.005_bib7","doi-asserted-by":"crossref","first-page":"13117","DOI":"10.1074\/jbc.RA119.008643","article-title":"N-Glycosylation regulates ligand-dependent activation and signaling of vascular endothelial growth factor receptor 2 (VEGFR2)","volume":"294","author":"Chandler","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2025.05.005_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.cell.2014.01.043","article-title":"Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors","volume":"156","author":"Croci","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2025.05.005_bib9","article-title":"Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2025.05.005_bib10","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/2159-8290.CD-20-0402","article-title":"Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers","volume":"10","author":"Song","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2025.05.005_bib11","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jamaoncol.2016.6108","article-title":"Comparison of Prevalence and Types of Mutations in Lung Cancers Among Black and White Populations","volume":"3","author":"Campbell","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chembiol.2025.05.005_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chembiol.2025.05.005_bib15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chembiol.2025.05.005_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.chembiol.2025.05.005_bib17","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1158\/2159-8290.CD-15-0399","article-title":"Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor","volume":"5","author":"Piotrowska","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.chembiol.2025.05.005_bib18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.chembiol.2025.05.005_bib19","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.chembiol.2025.05.005_bib20","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2025.05.005_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.03123","article-title":"Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review","volume":"38","author":"Piper-Vallillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1126\/science.aar7899","article-title":"Structural basis for coupling protein transport and N-glycosylation at the mammalian endoplasmic reticulum","volume":"360","author":"Braunger","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2025.05.005_bib23","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1126\/science.aaz3505","article-title":"Cryo-electron microscopy structures of human oligosaccharyltransferase complexes OST-A and OST-B","volume":"366","author":"Ram\u00edrez","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2025.05.005_bib24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cell.2008.11.047","article-title":"Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms","volume":"136","author":"Ruiz-Canada","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2025.05.005_bib25","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1083\/jcb.201404083","article-title":"Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins","volume":"206","author":"Cherepanova","year":"2014","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib26","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1083\/jcb.201301031","article-title":"Extreme C-terminal sites are posttranslocationally glycosylated by the STT3B isoform of the OST","volume":"201","author":"Shrimal","year":"2013","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib27","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/nchembio.2194","article-title":"Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells","volume":"12","author":"Lopez-Sambrooks","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib28","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/j.chembiol.2018.07.005","article-title":"Editing N-Glycan Site Occupancy with Small-Molecule Oligosaccharyltransferase Inhibitors","volume":"25","author":"Rinis","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib29","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1158\/1078-0432.CCR-09-3331","article-title":"Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy","volume":"16","author":"Contessa","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2025.05.005_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/1541-7786.MCR-16-0482","article-title":"Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation","volume":"15","author":"Yamaoka","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.chembiol.2025.05.005_bib31","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1038\/s41467-020-18442-4","article-title":"Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2025.05.005_bib32","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1158\/0008-5472.CAN-18-0505","article-title":"Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors","volume":"78","author":"Lopez Sambrooks","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2025.05.005_bib33","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1038\/s41467-022-34889-z","article-title":"Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer","volume":"13","author":"Adua","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chembiol.2025.05.005_bib35","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1158\/1078-0432.CCR-18-0792","article-title":"Oligosaccharyltransferase Inhibition Reduces Receptor Tyrosine Kinase Activation and Enhances Glioma Radiosensitivity","volume":"25","author":"Baro","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.chembiol.2025.05.005_bib34","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cell.2010.04.012","article-title":"Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints","volume":"141","author":"Zielinska","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2025.05.005_bib36","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1021\/acschembio.2c00479","article-title":"Proteomic and Phosphoproteomic Analyses Reveal the Oncogenic Role of PTK7-NDRG1 Axis in Non-small-cell Lung Cancer Cell Resistance to AZD9291","volume":"17","author":"Wang","year":"2022","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.chembiol.2025.05.005_bib38","first-page":"1669","article-title":"Biochemical effects and therapeutic potential of tunicamycin in murine L1210 leukemia","volume":"43","author":"Morin","year":"1983","journal-title":"Cancer Res."},{"key":"10.1016\/j.chembiol.2025.05.005_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.ade8079","article-title":"Signal recognition particle receptor-\u03b2 (SR-\u03b2) coordinates cotranslational N-glycosylation","volume":"9","author":"Phoomak","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.chembiol.2025.05.005_bib40","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.cell.2024.03.022","article-title":"Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-\u03baB","volume":"187","author":"Lampson","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.chembiol.2025.05.005_bib41","doi-asserted-by":"crossref","first-page":"21988","DOI":"10.1074\/jbc.M003400200","article-title":"The Asn-420-linked sugar chain in human epidermal growth factor receptor suppresses ligand-independent spontaneous oligomerization. Possible role of a specific sugar chain in controllable receptor activation","volume":"275","author":"Tsuda","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chembiol.2025.05.005_bib42","article-title":"A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC","volume":"3","author":"Lai","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.chembiol.2025.05.005_bib43","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Na\u00efve Patients With Advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.chembiol.2025.05.005_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc6364","article-title":"The translocon-associated protein (TRAP) complex regulates quality control of N-linked glycosylation during ER stress","volume":"7","author":"Phoomak","year":"2021","journal-title":"Sci. Adv."}],"container-title":["Cell Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945625001667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451945625001667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T13:28:06Z","timestamp":1750339686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451945625001667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2451945625001667"],"URL":"https:\/\/doi.org\/10.1016\/j.chembiol.2025.05.005","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.03.626593","asserted-by":"object"}]},"ISSN":["2451-9456"],"issn-type":[{"value":"2451-9456","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation","name":"articletitle","label":"Article Title"},{"value":"Cell Chemical Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chembiol.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}